# Phase 2a Pilot Study of NBMI Treatment in Patients With Beta Thalassemia Major, Requiring Iron Chelation

> **NCT04092205** · PHASE2 · COMPLETED · sponsor: **EmeraMed** · enrollment: 13 (actual)

## Conditions studied

- Beta Thalassemia Major

## Interventions

- **DRUG:** Emeramide

## Key facts

- **NCT ID:** NCT04092205
- **Lead sponsor:** EmeraMed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-21
- **Primary completion:** 2020-07-30
- **Final completion:** 2020-08-30
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2021-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04092205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04092205, "Phase 2a Pilot Study of NBMI Treatment in Patients With Beta Thalassemia Major, Requiring Iron Chelation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04092205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*